Patient Navigation for HER2+ Metastatic Breast Cancer Patients Treated With Tucatinib

Feasibility will be assessed by examining pilot study enrollment.

Feasibility will be assessed by examining retention (>80% completing 3 sessions).

Feasibility will be assessed by examining use of program strategies (≥75% reporting use of program skills and strategies).

Acceptability will be assessed using the Treatment Acceptability Questionnaire (TAQ). The program will be considered acceptable if >80% of participants rate the program as >5 out of 7 on the TAQ. A higher score indicates greater acceptability.

Acceptability will be assessed using the Client Satisfaction Questionnaire (CSQ). The program will be considered acceptable if >80% of participants rate the program as >3 out of 4 on the CSQ. A higher score indicates greater acceptability.

Knowledge will be assessed using an item pool developed for the study. Each participant will complete 10 items based on the education they received. Knowledge will be calculated as the percent of correct items.

Adherence will be measured for each drug in the regimen as discontinuation (yes/no).

For oral medications (i.e., tucatinib, capecitabine), medication taking behaviors (implementation adherence) will be measured using the Voils' medication adherence self-report measure which assesses the extent of (3 items) and reasons (18 items) for non-adherence.

The MDASI assesses the severity of symptoms at their worst in the last 24 hours on a 0-10 numerical rating scale, with 0 being "not present" and 10 being "as bad as you can imagine."

The MDASI measures how much the symptoms have interfered with six daily activities: general activity, mood, work, relations with others, walking, and enjoyment of life. Interference is rated on a 0-10 numerical rating scale, 0 being "did not interfere" and 10 being "interfered completely."

The HFS-14 score is calculated by summing the scores of all items and was adjusted to 100 by applying a rule of three. HFS-14 scores are in the range of 2-100, where a higher score indicates greater quality of life impairment.

The PROMIS Anxiety Short Form is scored by summing the individual item scores, with each item rated on a 1-5 Likert scale (never, rarely, sometimes, often, always). The total raw score ranges from 4 to 20, where higher scores indicate greater anxiety severity.

The PROMIS Depression Short Form is scored by summing the individual item scores, with each item rated on a 1-5 Likert scale (never, rarely, sometimes, often, always). The total raw score ranges from 4 to 20, where higher scores indicate greater depression severity.

Quality of life will be assessed using the Functional Assessment of Cancer Therapy - Breast (FACT-B). The FACT-B total score ranges from 0 to 148, where a higher score indicates better quality of life.

The PROMIS Self-efficacy for Managing Symptoms Short Form is scored by summing the individual item scores, with each item rated on a 1-5 Likert scale (never, rarely, sometimes, often, always). The total raw score ranges from 4 to 20, where higher scores indicate greater self-efficacy.

The PROMIS Self-efficacy for Managing Chronic Conditions Short Form is scored by summing the individual item scores, with each item rated on a 1-5 Likert scale (never, rarely, sometimes, often, always). The total raw score ranges from 4 to 20, where higher scores indicate greater self-efficacy.

The PAM assesses patients' knowledge, skills, and confidence central to managing their health and health care. Patients rate how much they agree or disagree with each item; raw scores are transformed to a score of 0-100, where a higher score indicates greater activation.